UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 12B-25

                           NOTIFICATION OF LATE FILING

(CHECK ONE):   / X/Form 10-KSB    / /Form 20-F    / /Form 11-K
               / /Form 10-QSB      / /Form N-SAR


For Period Ended: October 31, 2003
- ------------------------------
/  / Transition Report on Form 10-K
/  / Transition Report on Form 20-F
/  / Transition Report on Form 11-K
/  / Transition Report on Form 10-Q
/  / Transition Report on Form N-SAR

For the Transition Period Ended: _________________________

Read instruction (on back page) before preparing form. Please print or type.

Nothing in this form shall be construed to imply that the commission has
verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify
the Item(s) to which the notification relates:
- ------------------------------------------------------------------------

PART I -- REGISTRANT INFORMATION

Full Name of Registrant:  MERA PHARMACEUTICALS, INC.

Former Name if Applicable:  AQUASEARCH, INC.

Address of Principal Executive Office (Street and Number):
777 South Highway 101, Suite 215

City, State and Zip Code
Solana Beach, CA  92075








PART II -- RULES 12B-25(B) AND (C)

If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to Rule 12b-25(b), the following should
be completed. (Check box if appropriate)

            (a) The reasons described in reasonable detail in Part III of this
form could not be eliminated without unreasonable effort or expense;

/X/         (b) The subject annual report, semi-annual report, transition report
on Form 10-KSB, Form 20-F, 11-K or Form N-SAR, or portion thereof, will be filed
on or before the fifteenth calendar day following the prescribed due date; or
the subject quarterly report or transition report on Form 10-QSB, or portion
thereof will be filed on or before the fifth calendar day following the
prescribed due date; and

/ /         (c) The accountant's statement or other exhibit required by
Rule 12b-25(c) has been attached if applicable.


PART III -- NARRATIVE

State below in reasonable detail the reasons why Forms 10-KSB, 20-F, 11-K,
10-QSB, N-SAR, or the transition report or portion thereof, could not be filed
within the prescribed time period.

The independent audit of the financial statements of Mera Pharmaceuticals, Inc.
for the year ended October 31, 2003 has not been completed by the due date. The
Report on Form 10-KSB is expected to be filed on or before the fifteenth
calendar day following the prescribed due date.

(Attach extra sheets if needed) SEC 1344 (6/94)


PART IV -- OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this
notification

Daniel P Beharry                             (858) 847-0747
- --------------------              ----------------------------
           (Name) (Area Code) (Telephone Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the
Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of
1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed? If answer is no,
identify report(s). /X/ Yes / / No





(3) Is it anticipated that any significant change in results of operations from
the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion thereof? /
X/Yes / / No

Operating costs are expected to be reduced as a result of cost control measures.
The effect on earnings are not available as the Company's audit is not complete.



                                    Mera Pharmaceuticals, Inc.
                                    -------------------------------------
                                    (Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.

Date:  January 29, 2003                      By  /s/ Daniel P. Beharry
                                                   -----------------------
                                                   Daniel P. Beharry
                                                   Chief Executive Officer